A detailed history of Payden & Rygel Investment Group transactions in Eli Lilly & CO stock. As of the latest transaction made, Payden & Rygel Investment Group holds 24,220 shares of LLY stock, worth $21.5 Million. This represents 1.77% of its overall portfolio holdings.

Number of Shares
24,220
Previous 26,520 8.67%
Holding current value
$21.5 Million
Previous $20.6 Million 6.29%
% of portfolio
1.77%
Previous 0.97%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

SELL
$724.87 - $909.04 $1.67 Million - $2.09 Million
-2,300 Reduced 8.67%
24,220 $21.9 Million
Q1 2024

May 13, 2024

SELL
$592.2 - $792.28 $2.01 Million - $2.69 Million
-3,400 Reduced 11.36%
26,520 $20.6 Million
Q3 2023

Nov 08, 2023

BUY
$434.7 - $599.3 $13 Million - $17.9 Million
29,920 New
29,920 $16.1 Million

Others Institutions Holding LLY

About ELI LILLY & Co


  • Ticker LLY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 950,174,976
  • Market Cap $842B
  • Description
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...
More about LLY
Track This Portfolio

Track Payden & Rygel Investment Group Portfolio

Follow Payden & Rygel Investment Group and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Payden & Rygel Investment Group, based on Form 13F filings with the SEC.

News

Stay updated on Payden & Rygel Investment Group with notifications on news.